Brought to you by:
Search Results for abdominal aortic aneurysm
Endologix receives FDA Breakthrough Device designation for ChEVAS system
Endologix announced the company’s ChEVAS (chimney endovascular aneurysm sealing) system has been granted a Breakthrough Device designation from the Food and Drug Administration (FDA). The ChEVAS system is an investigational endovascular abdominal aortic aneurysm (AAA) sealing therapy designed to combine the Nellix 3.5 endograft…
Large study shows drop in AAA mortality ‘at faster rate than ever’
According to a new, population-based analysis, abdominal aortic aneurysm (AAA) mortality has continued to decline and “at a faster rate than ever” in the second decade of the 21st century. Authors C. Y. Maximilian Png, MD, a vascular surgery resident…
The top 10 most popular Vascular Specialist stories in May
A pointed letter aimed at electronic health record (EHR) behemoth Epic, an argument in favor of endovascular treatment of ruptured abdominal aortic aneurysms (rAAAs) and the first-ever Corner Stitch column were among the best-read stories here on the Vascular Specialist…
VAM plans for San Diego shape up: ‘The June gloom will be history’
Registration for the live, in-person 2021 Vascular Annual Meeting (VAM) has begun—and organizers promise you won’t want to miss the meeting. VAM will be Aug. 18 to 21 in beautiful San Diego, California. Educational programming will be presented across all…
Lead vascular surgeon on first use of Fiber Optic RealShape in US hails advance
Vascular surgeons at the University of Massachusetts became the first in the United States to carry out procedures using the breakthrough imaging technology Fiber Optic RealShape (FORS) last month, reporting a 75% decrease in fluoroscopy use after one of their…
The top 10 most popular stories from April
Our April cover story on the links between electronic health records (EHRs) and physician burnout, the continuing problem of manels (or all-male speaking panels) at vascular surgery meetings, and some of the latest details on the 2021 Vascular Annual Meeting…
Hitting the spot: EVAR for rAAA should be ‘treatment of choice’ in 2021
If the equipment and requisite skillset are available, and a patient’s anatomy is suitable, endovascular aneurysm repair (EVAR) for ruptured abdominal aortic aneurysms (rAAAs) “should be the treatment of choice in 2021 and beyond,” vascular titan Frank Veith, MD, argued…
Plans revealed for pilot study on performance of EVAR for AAA in office-based labs
Details of a planned pilot study investigating the merits of performing endovascular aortic repair (EVAR) on abdominal aortic aneurysms (AAAs) in office-based labs (OBLs) and other free-standing ambulatory facilities emerged during the recent Critical Issues America annual meeting (April 16–17)…
Registry data show EVAR is safe, durable and effective out to five years
Endovascular aortic repair (EVAR) is safe, durable and effective, the five-year interim results of the Global Registry for Endovascular Aortic Treatment (the GREAT registry) show. In this analysis of more than 3,000 abdominal aortic aneurysm (AAA) patients treated with an…
PAD: Endologix acquires PQ Bypass
Endologix recently announced completing the acquisition of PQ Bypass, a medical technology company pioneering a first-of-its-kind technology that addresses severe peripheral arterial disease (PAD). PQ Bypass’ proprietary Detour platform for percutaneous femoropopliteal bypass has been designated by the Food and…